318 related articles for article (PubMed ID: 32739118)
1. Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection.
Kim YH; Bang YJ; Park HJ; Li Ko H; Park SI; Hwang KA; Kim H; Nam JH
Vaccine; 2020 Sep; 38(39):6141-6152. PubMed ID: 32739118
[TBL] [Abstract][Full Text] [Related]
2. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
3. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
4. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
[TBL] [Abstract][Full Text] [Related]
5. The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.
Williams CM; Roy S; Califano D; McKenzie ANJ; Metzger DW; Furuya Y
J Virol; 2021 Oct; 95(22):e0059821. PubMed ID: 34468174
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
7. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
9. Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant.
Luo J; Liu XP; Xiong FF; Gao FX; Yi YL; Zhang M; Chen Z; Tan WS
Front Immunol; 2019; 10():2274. PubMed ID: 31611875
[TBL] [Abstract][Full Text] [Related]
10. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
11. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.
Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB
J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978
[TBL] [Abstract][Full Text] [Related]
12. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
13. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
14. Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.
Falkeborn T; Bråve A; Larsson M; Akerlind B; Schröder U; Hinkula J
PLoS One; 2013; 8(8):e70527. PubMed ID: 23950951
[TBL] [Abstract][Full Text] [Related]
15. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
16. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
17. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
18. Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response.
Kwak HW; Park HJ; Ko HL; Park H; Cha MH; Lee SM; Kang KW; Kim RH; Ryu SR; Kim HJ; Kim JO; Song M; Kim H; Jeong DG; Shin EC; Nam JH
Vaccine; 2019 Aug; 37(36):5191-5202. PubMed ID: 31371226
[TBL] [Abstract][Full Text] [Related]
19. Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine.
Chen F; Seong Seo H; Ji HJ; Yang E; Choi JA; Yang JS; Song M; Han SH; Lim S; Lim JH; Ahn KB
Hum Vaccin Immunother; 2021 Feb; 17(2):485-496. PubMed ID: 32643515
[TBL] [Abstract][Full Text] [Related]
20. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
Front Immunol; 2019; 10():646. PubMed ID: 30984200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
